Marking Eczema Awareness Month – Clinical Research Validates Strata Skin Sciences' XTRAC® Excimer Laser as a Breakthrough Therapy for Localized Atopic Dermatitis

Core Insights - STRATA Skin Sciences emphasizes the effectiveness of the XTRAC Excimer Laser for treating localized atopic dermatitis, supported by extensive clinical evidence [1][4] - The American Medical Association has expanded the excimer laser's indications, facilitating reimbursement for atopic dermatitis treatment through Medicare, Medicaid, and private payers [1] Company Overview - STRATA Skin Sciences is a medical technology company focused on innovative products for dermatologic conditions, including psoriasis, vitiligo, and acne [7] - The company offers a unique Partnership Program that includes a fee per treatment cost structure, on-site training, and marketing support [8] Market Context - Atopic dermatitis affects over 9.6 million children and 16.5 million adults in the U.S., significantly impacting their daily lives and emotional well-being [3] - Despite its prevalence, many patients face challenges with limited treatment options [3] Clinical Evidence - A study showed that excimer laser therapy resulted in an 81% reduction in itching intensity after one month, with significant quality-of-life improvements [5] - Another trial indicated that excimer laser treatment provided longer-lasting results compared to traditional steroid therapy, positioning it as a viable steroid-sparing option [5] - A pivotal study reported a 69% reduction in disease severity and 87% of patients achieving clear or almost clear skin after treatment [5] Treatment Advantages - The XTRAC Excimer Laser directly targets diseased skin while sparing healthy tissue, making it particularly effective for difficult areas like hands and feet [10] - The treatment offers lower UV exposure compared to whole-body phototherapy and provides shorter treatment regimens with long-lasting remission [10]